Antioxidant agent-8
Antioxidant agent-8 is an orally active inhibitor of Aβ1-42 deposition. Antioxidant agent-8 inhibits fibril aggregation (IC50=11.15 µM) and promotes fibril disaggregation (IC50=6.87 µM). Antioxidant agent-8 also inhibits Cu2+-induced Aβ1-42 fibril aggregation (IC50=3.69 µM) and promotes Cu2+-induced Aβ1-42 fibril disaggregation (IC50=3.35 µM). Antioxidant agent-8 has antioxidant activity, anti-inflammatory activity, biosafety, blood-brain barrier permeability and neuroprotective effect.
For research use only. We do not sell to patients.
- Formula: C13H12O5
- Molecular Weight:248.23
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Antioxidant agent-8 (compound 30) (50 µM; 24 h) selectively chelates with Cu2+, Fe2+, Zn2+, Fe3+ and Al3+ metal ions, significantly inhibits self- and Cu2+-induced Aβ1-42 fibril aggregation and disaggregation[1].
Antioxidant agent-8 (2.5, 5 and 10 µM; 24 h) promotes BV-2 cells to clear Aβ1-42, reduces Aβ1-42 induced apoptosis and protects nerves with concentration-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Mouse microglia BV-2 cells.
-
Concentration:2.5, 5 and 10 µM.
-
Incubation Time:24 h.
-
Result:Reduced the expression level of Aβ1-42 in cells.
-
Cell Line:Mouse microglia BV-2 cells.
-
Concentration:2.5, 5 and 10 µM.
-
Incubation Time:24 h.
-
Result:Significantly reduced Aβ1-42 induced apoptosis (cell apoptosis rate were below 30%).
-
Cell Line:Mouse microglia BV-2 cells.
-
Concentration:2.5, 5 and 10 µM.
-
Incubation Time:24 h.
-
Result:Promoted cell viability and the cell survival was 75.50 % (10 µM).
Antioxidant agent-8 (2000 mg/kg; i.g.; single dose) exhibits biosafety[1].
Antioxidant agent-8 (20 mg/kg; p.o.; once daily for 25 d) significantly improves anxiety, memory impairment and cognitive impairment caused by Scopolamine (HY-N0296)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley rats[1].
-
Dosage:15 mg/kg.
-
Administration:Intragastric administration; single dose.
-
Result:Appeared in plasma and hippocampus at 0.083, 0.167, 0.25, 0.5, 1, 2 and 4 hours after administration, and then gradually gathered in hippocampus.
-
Animal Model:Mice[1].
-
Dosage:2000 mg/kg.
-
Administration:Intragastric administration; single dose.
-
Result:Showed insignificant toxic and side effects on heart, liver, spleen and brain.
-
Animal Model:SCOP-induced cognitive impairment in ICR mice (25-28 g)[1].
-
Dosage:20 mg/kg.
-
Administration:Oral gavage; from day 7 to day 31, after 30 min of SCOP administration.
-
Result:Improved animal behavior, learning and memory.
Chemical Information
-
Molecular Weight 248.23
-
Formula C13H12O5
-
SMILES
O=C1CCOC(/C=C/C2=CC=C(C(O)=C2)O)=C1O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz